INTS12: A Potential Drug Target for Various Diseases (G57117)

Target Name: INTS12

NCBI ID: G57117

INTS12

INTS12: A Potential Drug Target for Various Diseases

INTS12 (SBBI22) is a protein that is expressed in various tissues of the body, including the brain. It is a member of the superfamily of RNA-protein interactions (SPI) and is involved in the regulation of gene expression. INTS12 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, INTS12 has become a focus of interest in the pharmaceutical industry and may be a potential drug target or biomarker.

The protein encoded by the INTS12 gene is a 22-kDa protein that contains 116 amino acid residues. It has a characteristic migratory behavior in SDS-PAGE gel electrophoresis, with a Mr of 18.9 kDa. The protein is predominantly expressed in the brain and other tissues of the body.

INTS12 is involved in the regulation of gene expression by interacting with various RNA molecules, including microRNAs and host RNAs. It has been shown to play a role in the regulation of neuronal differentiation and plasticity, as well as the regulation of synaptic plasticity.

INTS12 has also been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that INTS12 is involved in the development of neuroblastoma, a type of cancer that affects the neural stem cells that give rise to all nervous system cells.

In addition to its role in cancer, INTS12 has also been shown to be involved in the development of neurodegenerative diseases. For example, studies have shown that INTS12 is involved in the development of Alzheimer's disease, a neurodegenerative disorder that is characterized by the progressive loss of brain cells.

INTS12 has also been shown to be involved in the regulation of autoimmune disorders. For example, studies have shown that INTS12 is involved in the regulation of the immune response and that it plays a role in the development of autoimmune disorders.

Due to its involvement in the regulation of gene expression and its association with various diseases, INTS12 has become a focus of interest in the pharmaceutical industry. Researchers are actively searching for drugs that can modulate the activity of INTS12 and have identified several potential drug targets.

One of the potential drug targets for INTS12 is the inhibition of its activity with small molecule inhibitors. Studies have shown that INTS12 is highly sensitive to inhibition by small molecules, including inhibitors of tyrosine phosphorylation and inhibitors of its function as a negative regulator of microRNA translation . Therefore, small molecule inhibitors have the potential to be effective treatments for INTS12-related diseases.

Another potential drug target for INTS12 is the use of RNA-based therapeutics. Studies have shown that INTS12 is involved in the regulation of gene expression and that it can interact with small RNAs. Therefore, RNA-based therapeutics have the potential to be effective treatments for INTS12-related diseases.

In conclusion, INTS12 is a protein that is involved in the regulation of gene expression and has been shown to play a role in the development and progression of various diseases. As a result, INTS12 has become a focus of interest in the pharmaceutical industry and may be a potential drug target or biomarker. Further research is needed to fully understand the role of INTS12 in disease and to identify effective treatments for INTS12-related diseases.

Protein Name: Integrator Complex Subunit 12

Functions: Component of the Integrator complex, a complex involved in the small nuclear RNAs (snRNA) U1 and U2 transcription and in their 3'-box-dependent processing. The Integrator complex is associated with the C-terminal domain (CTD) of RNA polymerase II largest subunit (POLR2A) and is recruited to the U1 and U2 snRNAs genes (PubMed:16239144). Mediates recruitment of cytoplasmic dynein to the nuclear envelope, probably as component of the INT complex (PubMed:23904267)

The "INTS12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INTS12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets